A deep-dive into the 1999 Bunevicius crossover trial of levothyroxine plus liothyronine combination therapy, examining its real clinical implications, guideline responses, and which patients may benefit today.
Economic analysis of combination levothyroxine plus liothyronine therapy based on the 1999 Bunevicius trial: cost per QALY modeling, payer coverage barriers, list-price realities, and individual value calculations.
A deep-dive into the 1999 Bunevicius NEJM trial comparing levothyroxine plus liothyronine (T4+T3) to levothyroxine alone for hypothyroidism, covering methodology, results, limitations, and clinical relevance today.
Detailed breakdown of the Bunevicius 1999 trial results comparing T4+T3 combination therapy to T4 monotherapy, including effect sizes, secondary endpoints, and response patterns across cognitive and mood domains.
A deep-dive into the DAPA-HF trial examining how dapagliflozin reshaped heart failure treatment guidelines, prescribing patterns, and patient selection beyond the original 2019 NEJM publication.
A clinical-research deep dive into the real methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest considerations of the DAPA-HF trial of dapagliflozin in heart failure with reduced ejection fraction.
Deep dive into DAPA-HF follow-up and extension data for dapagliflozin in HFrEF, covering durability of benefit, long-term safety, and post-trial outcomes beyond the original 2019 NEJM publication.
Deep-dive into DAPA-HF pre-specified and post-hoc subgroup analyses by age, sex, BMI, diabetes status, race, and baseline biomarkers, revealing which heart failure patients benefit most from dapagliflozin.
Deep-dive into post-trial follow-up from DEVOTE: durability of degludec's CV safety signal, long-term hypoglycemia patterns, and what emerged after the key 2017 NEJM publication.
A deep dive into the DEVOTE trial's primary and secondary endpoint results, effect sizes, confidence intervals, subgroup analyses, and hypoglycemia outcomes for insulin degludec vs glargine U100 in type 2 diabetes.
How the ELITE trial's timing hypothesis for estradiol and atherosclerosis should reshape HRT prescribing decisions, guideline updates, and patient selection today.
A detailed examination of the ELITE trial's enrollment biases, statistical caveats, generalizability gaps, and what peer commentary revealed about this landmark early-HRT study.
Yes, EMPA-REG OUTCOME (n=7,020) showed empagliflozin cut CV death 38% and heart failure hospitalization 35% in type 2 diabetes patients with heart disease.
A critical analysis of the EMPA-REG OUTCOME trial's enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest considerations for empagliflozin in type 2 diabetes with cardiovascular disease.
Health-economic analyses of the EMPA-REG OUTCOME trial: cost per QALY for empagliflozin in type 2 diabetes with cardiovascular disease, payer coverage trends, and list-price vs net-price realities.
Deep dive into EMPA-REG OUTCOME follow-up data, durability of empagliflozin's cardiovascular and renal benefits, late safety signals, and long-term lessons from the landmark SGLT2 inhibitor trial.
A deep-dive overview of the EMPA-REG OUTCOME trial, the first SGLT2 inhibitor cardiovascular outcomes trial showing empagliflozin reduced major cardiac events in patients with type 2 diabetes and established heart disease.
Long-term follow-up from the EMPEROR-Preserved trial reveals durable empagliflozin benefits in HFpEF, emerging safety patterns, and unanswered questions about SGLT2 inhibitor therapy beyond the original 26-month median observation.
Plain-English breakdown of the EMPEROR-Preserved trial showing empagliflozin reduced CV death and heart failure hospitalization by 21% in patients with HFpEF.
A detailed breakdown of pre-specified and post-hoc subgroup analyses from the EMPEROR-Preserved trial of empagliflozin in HFpEF, examining which patient populations saw the greatest and smallest benefit.
A clinical-practice analysis of the Eun 2010 phase III RCT showing dutasteride 0.5 mg superiority over finasteride 1 mg for androgenetic alopecia, with guideline impact and prescribing implications.
A critical appraisal of the 2010 Eun et al. randomized trial comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, examining enrollment biases, follow-up gaps, statistical caveats, and conflict-of-interest considerations.
Long-term follow-up analysis of the Eun 2010 dutasteride vs finasteride trial for androgenetic alopecia: durability of hair count gains, late safety signals, and what post-trial data tell us about sustained 5-alpha reductase inhibition.
A detailed methodology analysis of the 2010 Eun et al. RCT comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, examining randomization, blinding, endpoint definition, and statistical approach.
A detailed breakdown of the Eun 2010 trial comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, including effect sizes, time-course data, and response distribution.
Eun’s 2010 dutasteride trial: reported hair-count results, the limits of subgroup claims, and differences from the Olsen and Gubelin Harcha trials.
A deep-dive into the Fracture Intervention Trial (FIT) of alendronate: methodology, real results, limitations, and what this foundational bisphosphonate trial means for prescribing decisions today.
A critical appraisal of the FIT trial for alendronate, examining enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
Deep-dive into cost-effectiveness analyses derived from the Fracture Intervention Trial (FIT), examining cost per QALY for alendronate, payer-coverage dynamics, and the real-world value calculation for patients considering bisphosphonate therapy.
Deep-dive into the FIT extension (FLEX) and long-term follow-up data for alendronate, covering durability of fracture protection, rebound risk after discontinuation, and late-emerging safety signals.
A deep methodological analysis of the FIT trial (1998 JAMA), examining how randomization, blinding, endpoint definitions, and statistical choices shaped the 47% vertebral fracture reduction finding for alendronate.
A deep-dive overview of the Fracture Intervention Trial (FIT), the landmark 1998 JAMA study that proved alendronate reduces vertebral fractures by 47% in postmenopausal women with osteoporosis.
A deep-dive into the Fracture Intervention Trial's primary and secondary endpoints for alendronate in postmenopausal osteoporosis, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of fracture reduction.
Deep-dive into the FIT trial's pre-specified and post-hoc subgroup analyses for alendronate, examining differential fracture reduction by age, baseline BMD, prior fracture status, BMI, and biomarkers.
How the FLOW trial's kidney outcomes with semaglutide should reshape prescribing for type 2 diabetes with CKD, which guidelines responded, and where evidence gaps remain.
A critical appraisal of the FLOW trial (semaglutide in T2D with CKD), covering enrollment biases, generalizability gaps, early stopping effects, sponsor involvement, and what post-publication commentary revealed.
Health-economic analysis of the FLOW trial: semaglutide cost per QALY in CKD with type 2 diabetes, payer-coverage gaps, list-price vs net-price realities, and patient-level value calculations.
Analysis of FLOW trial durability signals, post-trial follow-up implications, and long-term safety data for semaglutide in type 2 diabetes with chronic kidney disease.
A plain-English deep dive into the FLOW trial, the first RCT to show semaglutide slows kidney disease progression in people with type 2 diabetes and chronic kidney disease.
Deep-dive into the FLOW trial's pre-specified and post-hoc subgroup analyses, examining how age, sex, BMI, race/ethnicity, and baseline kidney function influenced semaglutide's renal outcomes in type 2 diabetes with CKD.
A deep-dive into the FOURIER trial of evolocumab (Repatha) in established ASCVD, examining how the 15% MACE reduction reshaped guidelines, prescribing patterns, and patient selection for PCSK9 inhibitors.
A clinical deep-dive into the enrollment biases, short follow-up, generalizability gaps, statistical nuances, and conflict-of-interest concerns raised about the FOURIER evolocumab cardiovascular outcomes trial.
A deep-dive into the FOURIER trial's randomization, blinding, endpoint adjudication, statistical design, and how each methodological choice shapes interpretation of evolocumab's 15% MACE reduction.
A deep-dive overview of the FOURIER trial, the landmark 27,564-patient RCT that proved evolocumab (a PCSK9 inhibitor) reduces heart attacks and strokes in patients already taking statins.
A deep dive into the FOURIER trial's primary and secondary endpoint results for evolocumab, including effect sizes, confidence intervals, time-course patterns, and subgroup analyses in 27,564 patients with established ASCVD.
Deep-dive into FOURIER trial pre-specified and post-hoc subgroup analyses for evolocumab, examining which patient populations saw the greatest and smallest MACE reductions by age, sex, BMI, baseline LDL-C, and more.
How the FREEDOM trial reshaped osteoporosis treatment guidelines, shifted prescribing patterns for denosumab, and what clinicians should consider for patients outside the original study population.
Deep dive into the FREEDOM trial extension: 10-year denosumab durability data, rebound vertebral fractures after discontinuation, and long-term safety signals including ONJ and atypical femoral fractures.
A detailed methodology breakdown of the FREEDOM trial (denosumab vs placebo for postmenopausal osteoporosis), covering randomization, blinding, endpoint definitions, statistical design, and how each choice shapes clinical interpretation.
A deep dive into the FREEDOM trial's primary and secondary endpoint data for denosumab in postmenopausal osteoporosis, including effect sizes, confidence intervals, subgroup analyses, and the time-course pattern of fracture reduction.
A critical appraisal of the HORIZON-PFT trial examining enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and what post-publication commentary revealed about yearly IV zoledronic acid for osteoporosis.
Deep dive into the HORIZON-PFT extension study: how zoledronic acid's fracture protection held up beyond 3 years, what safety signals emerged, and clinical implications for long-term bisphosphonate therapy.
Complete breakdown of HORIZON-PFT trial outcomes for zoledronic acid IV: primary and secondary endpoint effect sizes, confidence intervals, time-course data, and subgroup analyses from the landmark 2007 NEJM publication.
A clinical deep-dive into the methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest concerns surrounding the Heart Protection Study of simvastatin 40 mg.
A plain-English deep dive into the Heart Protection Study (HPS), the largest statin RCT ever conducted, which proved simvastatin 40 mg cut major vascular events by 24% across a remarkably broad range of high-risk patients.
A deep-dive into the Heart Protection Study's primary and secondary endpoint results, effect sizes, confidence intervals, subgroup analyses, and time-course patterns for simvastatin 40 mg in high-risk patients.
Deep-dive into Heart Protection Study pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline LDL, diabetes status, and vascular history. Which high-risk patients benefited most from simvastatin 40 mg?
A deep-dive into the IMPROVE-IT trial (ezetimibe + simvastatin vs simvastatin alone post-ACS) and what its 6.4% relative MACE reduction means for prescribing, guidelines, and patients outside the trial population.
A critical appraisal of IMPROVE-IT methodology, enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest considerations for ezetimibe plus simvastatin in post-ACS patients.
Long-term follow-up from the IMPROVE-IT trial reveals durable cardiovascular benefit of ezetimibe plus simvastatin, with no late safety signals and sustained MACE reduction beyond the original study period.